The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is the case for EGFR-mutated lung cancer: drugs based on biomolecules of a type known as tyrosine kinase inhibitor (TKI) have ...
Oct 5, 2020
0
6
A study led by researchers at the University of Kentucky Markey Cancer Center highlighted differences in patient diagnosis and treatment in those with non-small cell lung cancer (NSCLC) across the state of Kentucky.
Sep 23, 2020
0
0
According to a new study, mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment.
Aug 12, 2020
0
232
Researchers at the University of Alberta have found a way to deliver anti-cancer drugs with more precision, which could increase the effectiveness of many cancer treatments.
Jul 3, 2020
0
136
Two recently approved leukemia drugs could be enlisted against treatment-resistant lung cancer, with a clinical trial expected to launch in Toronto and Zagreb, Croatia, later this year to evaluate one of them.
Feb 24, 2020
0
122
Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous ...
Feb 7, 2020
0
1
Targeted, highly effective cancer treatments often produce debilitating side effects. This is the case with one commonly used therapy which works by blocking the epidermal growth factor receptor (EGFR), a protein that stimulates ...
Dec 12, 2019
0
68
No matter the pathogen—virus, bacterium or fungus—many "pick a specific type of lock" on the surface of cells, which allows the microbe to break and enter into the inner sanctum of the host's genome.
The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized. Dr. N. Rizvi from Columbia University Medical Center in New York today presented an update from ...
Sep 9, 2019
0
0
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ...
Aug 19, 2019
0
3
